deltatrials
Active Not Recruiting PHASE2 INTERVENTIONAL 1-arm NCT02344355

A Phase 2 Trial of High-Dose Ascorbate in Glioblastoma Multiforme

Pharmacological Ascorbate Combined With Radiation and Temozolomide in Glioblastoma Multiforme: A Phase 2 Trial

Sponsor: Bryan Allen

Conditions Glioblastoma Multiforme
Interventions Ascorbic Acid Temozolomide radiation therapy
Updated 19 times since 2017 Last updated: Dec 8, 2025 Started: Mar 13, 2017 Primary completion: Dec 31, 2026 Completion: Dec 31, 2028
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02344355, this PHASE2 trial focuses on Glioblastoma Multiforme and remains ongoing. Sponsored by Bryan Allen, it has been updated 19 times since 2017, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Mar 2017 · 28 days · monthly snapshot~Mar 2017 – ~May 2017 · 2 months · monthly snapshot~May 2017 – ~Jun 2018 · 13 months · monthly snapshot~Jun 2018 – ~May 2019 · 11 months · monthly snapshot~May 2019 – ~May 2020 · 12 months · monthly snapshot~May 2020 – ~Oct 2020 · 5 months · monthly snapshot~Oct 2020 – ~Jan 2021 · 3 months · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Feb 2022 · 12 months · monthly snapshot~Feb 2022 – ~Sep 2022 · 7 months · monthly snapshot~Sep 2022 – ~Aug 2023 · 11 months · monthly snapshot~Aug 2023 – ~Sep 2023 · 31 days · monthly snapshot~Sep 2023 – ~Dec 2023 · 3 months · monthly snapshot~Dec 2023 – ~Jul 2024 · 7 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Dec 2024 · 3 months · monthly snapshot~Dec 2024 – ~Jan 2026 · 13 months · monthly snapshot~Jan 2026 – present · 6 months · monthly snapshot

Change History

19 versions recorded

  1. Jan 2026 — Present [monthly]

    Active Not Recruiting PHASE2

  2. Dec 2024 — Jan 2026 [monthly]

    Active Not Recruiting PHASE2

  3. Sep 2024 — Dec 2024 [monthly]

    Active Not Recruiting PHASE2

  4. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE2

  5. Dec 2023 — Jul 2024 [monthly]

    Active Not Recruiting PHASE2

▶ Show 14 earlier versions

  1. Sep 2023 — Dec 2023 [monthly]

    Active Not Recruiting PHASE2

  2. Aug 2023 — Sep 2023 [monthly]

    Active Not Recruiting PHASE2

  3. Sep 2022 — Aug 2023 [monthly]

    Active Not Recruiting PHASE2

  4. Feb 2022 — Sep 2022 [monthly]

    Active Not Recruiting PHASE2

  5. Feb 2021 — Feb 2022 [monthly]

    Active Not Recruiting PHASE2

  6. Jan 2021 — Feb 2021 [monthly]

    Active Not Recruiting PHASE2

  7. Oct 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  8. May 2020 — Oct 2020 [monthly]

    Recruiting PHASE2

  9. May 2019 — May 2020 [monthly]

    Recruiting PHASE2

  10. Jun 2018 — May 2019 [monthly]

    Recruiting PHASE2

  11. May 2017 — Jun 2018 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  12. Mar 2017 — May 2017 [monthly]

    Not Yet Recruiting PHASE2

  13. Feb 2017 — Mar 2017 [monthly]

    Not Yet Recruiting PHASE2

  14. Jan 2017 — Feb 2017 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Bryan Allen
  • Gateway for Cancer Research
  • Holden Comprehensive Cancer Center
  • National Cancer Institute (NCI)
Data source: University of Iowa

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations